Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00367887 · ClinicalTrials.gov registry record · Phase 2

A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects

A Phase 2 study of Hepatitis C, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

Completed
Registry status
Phase 2
Development phase
246
Enrollment target
20
Study locations

NCT00367887 is a Phase 2 study of Hepatitis C that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 246 participants, below the 1,888-participant average among 106 other Hepatitis C trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00367887, a Phase 2 study of Hepatitis C, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
246 participants
Enrollment target
20
Study locations

Study Summary

This is a phase 2, randomized, open-label study comparing the safety, antiviral activity, and pharmacokinetics of HCV-796 administered in combination with peginterferon alfa 2B (Peg-Intron) plus concomitant Rebetol vs. Peg-Intron plus Rebetol in Hepatitis C Virus (HCV) genotype 1-infected subjects who are either naive to treatment or who have previously failed treatment (non-responders).

Conditions Studied

Hepatitis C

Interventions

  • DRUG Peg-Intron
  • DRUG REBETOL
  • DRUG HCV 796

Study Locations (20)

California

  • Pfizer Investigational Site - Anaheim
  • Pfizer Investigational Site - La Jolla
  • Pfizer Investigational Site - La Jolla
  • Pfizer Investigational Site - Los Angeles
  • Pfizer Investigational Site - Pasadena
  • Pfizer Investigational Site - San Diego
  • Pfizer Investigational Site - San Diego
  • Pfizer Investigational Site - San Francisco
  • Pfizer Investigational Site - San Francisco

Florida

  • Pfizer Investigational Site - Gainesville
  • Pfizer Investigational Site - Miami

Massachusetts

  • Pfizer Investigational Site - Boston
  • Pfizer Investigational Site - Worcester

Minnesota

  • Pfizer Investigational Site - Plymouth
  • Pfizer Investigational Site - Saint Paul

District of Columbia

  • Pfizer Investigational Site - Washington D.C.

Georgia

  • Pfizer Investigational Site - Atlanta

Kentucky

  • Pfizer Investigational Site - Louisville

Michigan

  • Pfizer Investigational Site - Detroit

Trial Details

FieldValue
Enrollment Target 246 participants
Start Date 2006-10
Est. Completion 2008-07
Phase Phase 2

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

167 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00367887

The ClinicalTrials.gov registry entry for NCT00367887 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 246 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,888-participant average among 106 other Hepatitis C trials with a reported enrollment target (87% lower). The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hepatitis C appearing as the primary indexed condition, and to 3 interventions - of which Peg-Intron is the first listed.

NCT00367887 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00367887 about?

NCT00367887 is a clinical study titled "A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects". This is a phase 2, randomized, open-label study comparing the safety, antiviral activity, and pharmacokinetics of HCV-796 administered in combination with peginterferon alfa 2B (Peg-Intron) plus concomitant Rebetol vs. Peg-Intron plus Rebetol in Hepatitis C Virus (HCV) genotype 1-infected subjects ...

What is the current status of trial NCT00367887?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 246 participants. The study started on 2006-10. Estimated completion is 2008-07.

What conditions does trial NCT00367887 study?

This clinical trial studies the following conditions: Hepatitis C.

What interventions are being tested in trial NCT00367887?

The interventions under investigation include: Peg-Intron (DRUG), REBETOL (DRUG), HCV 796 (DRUG).

Who is sponsoring clinical trial NCT00367887?

This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00367887 being conducted?

This trial has 20 study locations across California, District of Columbia, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatitis C

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hepatitis C

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.